Compare Avantis International Small Cap Value ETF (AVDV) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Biogen Inc — how do they compare? Avantis International Small Cap Value ETF trades at $110.2, while Biogen Inc trades at $204.1 (market cap $30.13B). The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| AVDV | BIIB | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $216.63 |
52-Week Low | $83.89 | $128.93 |
Market Cap | — | $30.13B |
Enterprise Value | — | $37.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $110.27, up 0.74% today, with a bullish technical signal from moving averages but caution from oscillators like the 6-day RSI at 87.64 indicating overbought conditions. Recent news highlights strong 2026 performance, with international small-cap value strategies delivering 35% gains and dividends. The fund focuses on cheap, profitable small companies in developed markets outside the U.S., benefiting from diversification and value exposure.
The outlook remains positive due to historical outperformance and dividend yield, but risks include overbought technicals and reliance on global economic stability. Investors should weigh the fund's value approach against potential volatility in international small caps, with support near $108 providing a cushion for pullbacks.
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
